SEC Company Response from AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702) (FFR) — Jun 22, 2015
AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702)
Date: June 22, 2015 · CIK: 0001460702 · Accession: 0001571049-15-005223
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-202924
Letter
Securities and Exchange Commission Division of Corporate Finance Attention: Mr. Johnny Gharib Mr. Brian Pitko Filed on Form S-1 Registration No. 333-202924
Re: Ritter Pharmaceuticals, Inc. (the “Company”)
Dear Mr. Gharib,
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the underwriters in connection with the offering pursuant to the above-captioned Registration Statement, hereby joins in the request of Ritter Pharmaceuticals, Inc. that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. Eastern Time on June 23, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there has been distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
[Signature page follows]
Very truly yours,
Aegis Capital Corp., as joint book-
Show Raw Text
CORRESP 1 filename1.htm June 22, 2015 Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549-7010 Attention: Mr. Johnny Gharib Mr. Brian Pitko Re: Ritter Pharmaceuticals, Inc. (the “Company”) Filed on Form S-1 Registration No. 333-202924 Dear Mr. Gharib, Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the underwriters in connection with the offering pursuant to the above-captioned Registration Statement, hereby joins in the request of Ritter Pharmaceuticals, Inc. that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. Eastern Time on June 23, 2015, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that there has been distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. [Signature page follows] Very truly yours, Aegis Capital Corp., as joint book- running manager and representative of the underwriters By: /s/ Eugene Terracciano Name: Eugene Terracciano Title: Chief Compliance Officer